There are currently 702 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
NCT05219617
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/20/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Seizures, Lennox Gastaut Syndrome
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Orlando Health Cancer Institute, Orlando, Florida
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Telehealth-Delivered Gut-Directed Hypnotherapy for Managing GI Health
NCT06890663
Recruiting
This study aims to evaluate the specific and non-specific effects of hypnotherapy and to evaluate the efficacy of group-format gut-directed hypnotherapy (GDH) delivered via telehealth for managing gastrointestinal health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Central Florida, Orlando, Florida
Conditions: Gastrointestinal Disease, Gastrointestinal Disorders, Nervous System
Register for Updates
Capability Assessment for Diet and Activity (CADA) Model for Diabetes
NCT06631105
Recruiting
This study investigates the capabilities related to diet, physical activity, screening, and knowledge among diabetic adults with or without a history of hospital admissions in Central Florida. The hypothesis is that enhancing these capabilities, based on the Capability Approach framework, can significantly reduce hospital readmissions and improve diabetes management outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Central Florida, Orlando, Florida
Conditions: Diabetes
Register for Updates
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348
Recruiting
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Conquest Research LLC, Orlando, Florida
Conditions: Chemotherapy Induced Neuropathic Pain
Register for Updates
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989
Recruiting
This is a retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing cryoablation of the intercostal nerves (cryoanalgesia) for post-operative pain management.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/18/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Post Operative Pain
Register for Updates
Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
NCT05565417
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Site 4100, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Register for Updates
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194
Recruiting
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often pr... Read More
Gender:
ALL
Ages:
Between 15 years and 40 years
Trial Updated:
03/18/2025
Locations: AdventHealth Orlando, Orlando, Florida +1 locations
Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Register for Updates
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Nemours Children's Hospital, Orlando, Florida
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Florida Institute for Clinical Research, Orlando, Florida
Conditions: Severe Hypertriglyceridemia
Register for Updates
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
NCT06602141
Recruiting
The purpose of this research study is to study the effects of endurance exercise training on adipose (fat) tissue quality and insulin sensitivity in men and women.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/17/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Obesity
Register for Updates
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
NCT04408625
Recruiting
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.... Read More
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
03/14/2025
Locations: PPD Phase 1 Clinic, 100 West Gore Street, Suite 202, Orlando, Florida
Conditions: Frontotemporal Dementia
Register for Updates